Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 26, 2021

View Archived Issues

Neuron-specific delivery platform based on a chimeric toxin for botulism postexposure treatment

Incyte initiates phase I/II study of INCB-000928 in patients with anemia due to MF

Phase I trial investigates NNC0361-0041 for type 1 diabetes

Study links ALS gene to tumor suppressor, transcription changes

Membrane rupture is active event

Xarelto approved in Japan to treat children with VTE and to prevent VTE recurrence

Exelixis initiates first-in-human study of XL-102 in advanced or metastatic solid tumors

Bavencio approved in Europe as first-line maintenance for urothelial carcinoma

UCB patents dopamine D1 receptor PAMs

Roche synthesizes MGL inhibitors

Progen presents new fusion proteins for autoimmune diseases

Chinese researchers present CAR T-cell therapy for cancer

AR agonist-based strategy proposed for ER+ breast cancer

Zymso approved in Japan for interstitial cystitis

Merck & Co. discontinues development of V-590 and V-591 vaccine candidates

New NFE2L2 activators patented by Senju Pharmaceutical

Dosing begins in phase II study of MVC-COV-1901 vaccine in Taiwan

StemVacs induces regression of glioma, lung and colorectal cancer tumors in vivo

Ivermectin use tied to lower mortality in patients with COVID-19

5-HT2B as a novel therapeutic target to improve microstructural remodeling post-MI

Dosing begins in phase I study of TJ-210 in advanced solid tumors

Rinvoq approved in E.U. for psoriatic arthritis and ankylosing spondylitis

Curadigm's Nanoprimer-based project selected for Sanofi iTech Awards program

One-year data from SPIRIT Extension study of relugolix combination therapy in endometriosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...